Abstracts tagged "adalimumab and economics"

Abstract Number: 1047 • ACR/ARHP Annual Meeting 2017
Cost-Effectiveness of Drug-Level Guided Adalimumab Dosing
Zara Izadi¹, Gabriela Schmajuk², Milena Gianfrancesco³, Laura Trupin⁴, Kashif Jafri⁵, Jinoos Yazdany⁴ and Dhruv Kazi⁶, ¹Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ²San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ⁵University of California, San Francisco, San Francisco, CA, ⁶Department of Medicine, University of California, San Francisco, Zuckerberg San Francisco General Hospital, San Francisco, CA
Background/Purpose: Adalimumab (ADA) induces and maintains clinical remission in patients with rheumatoid arthritis (RA) and Crohn’s disease (CD) but is an expensive drug. Drug-level and…
Abstract Number: 1771 • ACR/ARHP Annual Meeting 2013
Cost-Effectiveness Of Different Treatment Sequences Including Adalimumab In The Treat-To-Target Framework For Early Rheumatoid Arthritis In Germany
Malte Wolff¹, Zheng-Yi Zhou², James Signorovitch², James W. Shaw³ and Arijit Ganguli³, ¹AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ²Analysis Group, Inc., Boston, MA, ³AbbVie Inc., North Chicago, IL
Background/Purpose: The 2012 German rheumatoid arthritis (RA) treatment guidelines recommend sequential use of disease-modifying antirheumatic drugs (DMARDs) in a treat-to-target (T2T) framework. Biologics are recommended…